Clinical trials: ANCA-associated Vasculitis
Kidney Failure, Acute
Comparison of ANCA and Anti-GBM Auto-antibodies Removal Kinetics Between Plasma Exchanges and Immunoadsorption in Patients With ANCA-associated Vasculitis or Anti-GBM Disease
Anti-neutrophil cytoplasmic antibodies (ANCA), directed against myeloperoxidase (MPO) and against proteinase 3 (PR3), have a pathogenic role during ANCA (AAV) vasculitis.
- Trial name
- CINEVAS (NCT03635385)
- Testing
- Apheresis technics
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Microscopic Polyangiitis
Low-dose Glucocorticoid Vasculitis Induction Study
Previous reports suggested conventional immunosuppressants such as cyclophosphamide could not reduce glucocorticoid dose in remission induction in ANCA-associated vasculitis because of lower remission rate and higher relapse…
- Conditions
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Microscopic Polyangiitis, Wegener Granulomatosis
- Trial name
- LoVAS (NCT02198248)
- Testing
- Rituximab, Glucocorticoids
- Where
- 17 sites in Japan
- Volunteers
- 140 people
- Sponsor
- Chiba University
Granulomatosis With Polyangiitis
Obinutuzumab for Remission Induction in Patients With Relapsing PR3-ANCA Granulomatosis With Polyangiitis
The purpose of this study is to evaluate the efficacy and safety of obinutuzumab to induce clinical and serological remission in patients with relapsing PR3-ANCA granulomatosis with polyangiitis.
- Trial name
- OBI-WAN (NCT06940661)
- Testing
- Obinutuzumab
- Where
- France
- Volunteers
- 33 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Systemic Lupus Erythematosus, Systemic Scleroderma
Characterization of Autoreactive b Lymphocytes in Autoimmune Diseases and Immune Deficiencies
Autoimmune diseases (AID), whether systemic or organ-specific, affect approximately one in ten people, and their prevalence continues to increase.
- Conditions
- Systemic Lupus Erythematosus, Systemic Scleroderma, ANCA-associated Vasculitis, Antiphospholipid Syndrome
- Trial name
- AutoB-Tetramer (NCT07251179)
- Testing
- blood draw
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Strasbourg, France
Rheumatoid Arthritis, Ankylosing Spondylitis
PatientSpot Formerly Known as ArthritisPower
Patient Power is a patient research network and database (registry) to collect prospective information about demographics, self-reported diagnoses and medications, and willingness to participate in research from participants with…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout
- Trial name
- NCT03840928
- Where
- United States
- Volunteers
- 40,000 people, healthy volunteers welcome
- Sponsor
- Global Healthy Living Foundation
Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
This study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), including LN and SLE-ITP, Sjogren's Syndrome, etc.
- Conditions
- Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Sjogren's Syndrome (SS), Inflammatory Myopathy
- Trial name
- NCT07123519
- Testing
- YTS109 cell
- Where
- China
- Volunteers
- 18 people
- Sponsor
- China Immunotech (Beijing) Biotechnology Co., Ltd.
ANCA-associated Vasculitis, Granulomatosis With Polyangiitis
Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator
The goal of this multicentre observational study is to compare the safety and effectiveness of rituximab biosimilars to the originator in Canadian patients with Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis…
- Conditions
- ANCA-associated Vasculitis, Granulomatosis With Polyangiitis, Microscopic Polyangiitis
- Trial name
- BRAVO (NCT05716334)
- Where
- 9 sites in Canada
- Volunteers
- 201 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab
The purpose of this research study is to see if Eculizumab (Soliris®) can safely be used in addition to conventional therapy in patients with active ANCA (Antineutrophil Cytoplasmic Autoantibodies ) vasculitis and lead to a more…
- Trial name
- NCT01275287
- Testing
- Standard of care treatment, eculizumab
- Where
- United States
- Sponsor
- University of North Carolina, Chapel Hill
Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
A Study of CCX168 in Japanese and Caucasian Healthy Adult Males
The objectives of the study will be to investigate the safety and pharmacokinetics of a single oral administration and a twice-daily multiple oral administration of CCX168 in Japanese healthy adult males; and to compare the…
- Trial name
- NCT05988008
- Testing
- CCX168
- Where
- Japan
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Amgen
Systemic Lupus Erythematosus (SLE), Systemic Sclerosis
Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases
This study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), including LN and SLE-ITP, Sjogren's Syndrome, etc.
- Conditions
- Systemic Lupus Erythematosus (SLE), Systemic Sclerosis, Sjogren's Syndrome (SS), Inflammatory Myopathy
- Trial name
- NCT07236801
- Testing
- YTS109 cell
- Where
- 2 sites in China
- Volunteers
- 18 people
- Sponsor
- China Immunotech (Beijing) Biotechnology Co., Ltd.
ANCA Associated Vasculitis, Sjogren's Syndrome
Patients With Co-occurrence of ANCA Vasculitis and Sjögren Syndrome
ANCA vasculitis and Sjögren syndrome are two rare diseases, and even more rarely associated. These two conditions have specific organ involvements, and specific follow-up.
- Trial name
- NCT04895878
- Where
- France
- Volunteers
- 5 people
- Sponsor
- University Hospital, Montpellier
Churg-Strauss Syndrome, Eosinophilic Granulomatosis With Polyangiitis
NUCALA® Special Drug Use Investigation (EGPA, Long-term)
This study is a drug use investigation program of NUCALA. The objective of this study is to collect and assess information on the safety and effectiveness of the long-term use of NUCALA SC injection in daily clinical practice in…
- Trial name
- NCT03557060
- Testing
- Nucala
- Where
- Japan
- Volunteers
- 4,115 people
- Sponsor
- GlaxoSmithKline
Granulomatosis With Polyangiitis
Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis)
Anti-neutrophil cytoplasm antibodies (ANCA)-associated vasculitis are rare diseases characterized by inflammation of blood vessels.
- Trial name
- NeutroVasc (NCT01862068)
- Testing
- Blood samples and clinical data, Blood sample
- Where
- France
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
ANCA Associated Systemic Vasculitis, Wegener's Granulomatosis
Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides
A comparison of intermittent pulsed cyclophosphamide to daily oral cyclophosphamide for the treatment of ANCA-associated systemic vasculitides with kidney involvement. Performed by the European Vasculitis Study group.
- Conditions
- ANCA Associated Systemic Vasculitis, Wegener's Granulomatosis, Microscopic Polyangiitis
- Trial name
- NCT00430105
- Testing
- cyclophosphamide
- Volunteers
- 160 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
ANCA-associated Vasculitis
Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis
The aim of the trial is to study the efficacy and safety of treatment with BDB-001 Injection substitution of glucocorticoid in patients with ANCA-associated vasculitis.
- Trial name
- NCT05197842
- Testing
- BDB-001 injection, Cyclophosphamide, Glucocorticoids
- Where
- 22 sites in China
- Volunteers
- 93 people
- Sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd
Churg Strauss Syndrome
Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome
The purpose of this study is to determine whether Mepolizumab (a monoclonal antibody against interleukin-5) is a safe and well-tolerated therapy that will allow for steroid tapering in patients with steroid-dependent…
- Trial name
- MATOCSS (NCT00527566)
- Testing
- Mepolizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Brigham and Women's Hospital
ANCA Associated Vasculitis (AAV)
BDB-001 Phase III Trial in ANCA-Associated Vasculitis
The primary aim is to study the efficacy of treatment with BDB-001 Injection to induce remission in patients with active anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), when used in combination with…
- Trial name
- NCT07168161
- Testing
- BDB-001 injection, Cyclophosphamide, Rituximab
- Where
- 65 sites in China
- Volunteers
- 300 people
- Sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd
Granulomatosis With Polyangiitis, Wegener Granulomatosis
TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With Polyangiitis
Granulomatosis with polyangiitis (GPA; Wegener's) is a multi-organ autoimmune disease characterized by necrotizing granulomatous inflammation and vasculitis.
- Trial name
- TEMPO (NCT03919435)
- Testing
- Trimethoprim Sulfamethoxazole
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Pennsylvania